TITLE

Protease-Activated Receptor 1 Inhibition by SCH79797 Attenuates Left Ventricular Remodeling and Profibrotic Activities of Cardiac Fibroblasts

AUTHOR(S)
Sonin, Dmitry L.; Wakatsuki, Tetsuro; Routhu, Kasi V.; Harmann, Leanne M.; Petersen, Matthew; Meyer, Jennifer; Strande, Jennifer L.
PUB. DATE
September 2013
SOURCE
Journal of Cardiovascular Pharmacology & Therapeutics;Sep2013, Vol. 18 Issue 5, p460
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Fibroblast activity promotes adverse left ventricular (LV) remodeling that underlies the development of ischemiccardiomyopathy. Transforming growth factor-β (TGF-β) is a potent stimulus for fibrosis, and the extracellular signal-regulatedkinases(ERK) 1/2 pathway also contributes to the fibrotic response. The thrombin receptor, protease-activated receptor 1(PAR1), has been shown to play an important role in the excessive fibrosis in different tissues. The aim of this study was to investigatethe influence of a PAR1 inhibitor, SCH79797, on cardiac fibrosis, tissue stiffness and postinfarction remodeling, and effectsof PAR1 inhibition on thrombin-induced TGF-β and (ERK) 1/2 activities in cardiac fibroblasts. Methods: We used a rat model ofmyocardial ischemia-reperfusion injury, isolated cardiac fibroblasts, and 3-dimensional (3D) cardiac tissue models fabricated toascertain the contribution of PAR1 activation on cardiac fibrosis and LV remodeling. Results: The PAR1 inhibitor attenuated LVdilation and improved LV systolic function of the reperfused myocardium at 28 days. This improvement was associated with anonsignificant decrease in scar size (%LV) from 23±% in the control group (n = 10) to 16%±5.5% in the treated group (n = 9;P = .052). In the short term, the PAR1 inhibitor did not rescue infarct size or LV systolic function after 3 days. The PAR1 inhibitionabolished thrombin-mediated ERK1/2 phosphorylation, TGF-β and type I procollagen production, matrix metalloproteinase-2/9activation, myofibroblasts transformation in vitro, and abrogated the remodeling of 3D tissues induced by chronic thrombin treatment.Conclusion: These studies suggest PAR1 inhibition initiated after ischemic injury attenuates adverse LV remodelingthrough late-stage antifibrotic events.
ACCESSION #
89701312

 

Related Articles

  • IL-13 Induces YY1 through the AKT Pathway in Lung Fibroblasts. Guo, Jia; Yao, Hongwei; Lin, Xin; Xu, Haodong; Dean, David; Zhu, Zhou; Liu, Gang; Sime, Patricia // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    A key feature of lung fibrosis is the accumulation of myofibroblasts. Interleukin 13 (IL-13) is a pro-fibrotic mediator that directly and indirectly influences the activation of myofibroblasts. Transforming growth factor beta (TGF-β) promotes the differentiation of fibroblasts into...

  • Pulmonary fibrosis: molecular mechanisms.  // Thorax;Dec2004 Supplement, Vol. 59, p41 

    The article presents abstracts of papers on the molecular mechanism of pulmonary fibrosis. One of the studies report on idiopathic pulmonary fibrosis, which is a progressive fibrotic lung disease that poses a therapeutic challenge because no treatment has a consistent impact on disease...

  • Basic mechanisms in interstitial lung disease.  // Thorax;Dec2007 Supp, Vol. 62, pA23 

    The article presents abstracts on medical topics which include the effect of oxidative stress on transforming growth factor-beta expression, the differential modulation of lung fibroblast and alveolar epithelial cell apoptosis by cyclooxygenase-2 and serum biomarkers in systemic...

  • Myelofibrosis with myeloid metaplasia. Lock, Gareth; Kendrick, Chris // New Zealand Journal of Medical Laboratory Science;2006, Vol. 60 Issue 1, p3 

    Myelofibrosis with myeloid metaplasia (MMM) is a member of the chronic myeloproliferative disorder group as defined by the World Health Organisation. The disease is uncommon and is initially characterised by anaemia and cytopenia caused by the over-expression of growth factors released by...

  • The underlying cellular mechanism of fibrosis. RODEMANN, H. PETER; BINDER, ANKE; BURGER, ANKE; GÜVEN, NURI; LÖFFLER, HEIDI; BAMBERG, MICHAEL // Kidney International Supplement;May1996, Issue 54, pS-32 

    Fibrosis is a common sequela of various exogenous insults to a variety of parenchymal tissues. The underlying mechanisms of the induction and progression of fibrosis both at the molecular and cellular level have not been clarified so far. In the present study the cellular level have not been...

  • Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway. Kim, Dal; Lee, Ae Sin; Jung, Yu Jin; Yang, Kyoung Hee; Lee, Sik; Park, Sung Kwang; Kim, Won; Kang, Kyung Pyo // Nephrology Dialysis Transplantation;Nov2014, Vol. 29 Issue 11, p2043 

    Background After insult to the kidney, a renal fibrotic process is initiated with sustained inflammation, fibroblast activation and accumulation of extracellular matrix (ECM). Tamoxifen has been used as an anti-estrogen for the prevention and treatment of breast cancer. In this study, we...

  • Halting renal fibrosis: an unexpected role for mTORC2 signaling. Grahammer, Florian // Kidney International;Sep2015, Vol. 88 Issue 3, p437 

    Slowly progressive renal fibrosis is the hallmark of chronic kidney disease, independent of its etiology. Transforming growth factor-β (TGF-β) has been found to be the main profibrotic renal cytokine. Li et al. identify mTORC2 as an important mediator of TGF-β signaling. Being upstream...

  • The pro-fibrotic properties of transforming growth factor on human fibroblasts are counteracted by caffeic acid by inhibiting myofibroblast formation and collagen synthesis. Mia, Masum; Bank, Ruud // Cell & Tissue Research;Mar2016, Vol. 363 Issue 3, p775 

    Fibrosis is a chronic disorder affecting many organs. A universal process in fibrosis is the formation of myofibroblasts and the subsequent collagen deposition by these cells. Transforming growth factor beta1 (TGFβ1) plays a major role in the formation of myofibroblasts, e.g. by activating...

  • MicroRNA-155 inhibits the pro-fibrogenic activities of TGF-β1 in human lung fibroblasts. Li Chu; Ye Li; Xiaofei Zhang; Xiaolong Fu; Zhengfei Zhu // International Journal of Clinical & Experimental Medicine;2017, Vol. 10 Issue 1, p347 

    Transforming growth factor-β1 (TGF-β1) stimulates extracellular matrix production, and is considered a master regulator of tissue fibrosis, including idiopathic pulmonary fibrosis and radiation-induced fibrosis. A recent study identified dysregulated miR-155 expression during pulmonary...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics